Publications

@article{Sondo2022,

title = {Boosting the impact of seasonal malaria chemoprevention (SMC) through simultaneous screening and treatment of household members of children receiving SMC in Burkina Faso: a protocol for a randomized open label trial},

author = {Paul Sondo and Marc Christian Tahita and Hamidou Ilboudo and Toussaint Rouamba and Karim Derra and Gauthier Tougri and Florence Ou\'{e}draogo and B\'{e}atrice Marie Ad\'{e}la\"{i}de Konseibo and Eli Roamba and Sabina Dahlstr\"{o}m Otienoburu and B\'{e}renger Kabor\'{e} and Kalynn Kennon and Kadija Ou\'{e}draogo and Wend-Timbe-Noma Arlette Ra\"{i}ssa Zongo and Fadima Yaya Bocoum and Kasia Stepniewska and Mehul Dhorda and Philippe J. Gu\'{e}rin and Halidou Tinto},

url = {https://archpublichealth.biomedcentral.com/articles/10.1186/s13690-022-00800-x},

doi = {10.1186/s13690-022-00800-x},

issn = {2049-3258},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Archives of Public Health},

volume = {80},

issue = {1},

pages = {41},

abstract = {BACKGROUND Plasmodium falciparum malaria remains a major public health concern in sub-Sahara Africa. Seasonal malaria chemoprevention (SMC) with amodiaquine + sulfadoxine-pyrimethamine is one of the most important preventive interventions. Despite its implementation, the burden of malaria is still very high in children under five years old in Burkina Faso, suggesting that the expected impact of this promising strategy might not be attained. Development of innovative strategies to improve the efficacy of these existing malaria control measures is essential. In such context, we postulate that screening and treatment of malaria in household members of children receiving SMC could greatly improve the impact of SMC intervention and reduce malaria transmission in endemic settings. METHODS This randomized superiority trial will be carried out in the Nanoro health district, Burkina Faso. The unit of randomisation will be the household and all eligible children from a household will be allocated to the same study group. Households with 3-59 months old children will be assigned to either (i) control group (SMC alone) or (ii) intervention (SMC+ screening of household members with standard Histidin Rich Protein Rapid Diagnostic Test (HRP2-RDT) and treatment if positive). The sample size will be 526 isolated households per arm, i.e., around 1052 children under SMC coverage and an expected 1315 household members. Included children will be followed-up for 24 months to fully cover two consecutive malaria transmission seasons and two SMC cycles. Children will be actively followed-up during the malaria transmission seasons while in the dry seasons the follow-up will be passive. CONCLUSION The study will respond to a major public health concern by providing evidence of the efficacy of an innovative strategy to boost the impact of SMC intervention.},

keywords = {Africa, Amodiaquine, Burkina Faso, Chemoprevention, Dihydro artemisinin Piperaquine, Malaria, Plasmodium falciparum, Sulfadoxine-pyrimethamine},

pubstate = {published},

tppubtype = {article}

}

@article{Adjuik2015,

title = {The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: A meta-analysis of individual patient data},

author = {Martin A. Adjuik and Richard Allan and Anupkumar R. Anvikar and Elizabeth A. Ashley and Mamadou S. Ba and Hubert Barennes and Karen I. Barnes and Quique Bassat and Elisabeth Baudin and Anders Bj\"{o}rkman and Fran\c{c}ois Bompart and Maryline Bonnet and Steffen Borrmann and Philippe Brasseur and Hasifa Bukirwa and Francesco Checchi and Michel Cot and Prabin Dahal and Umberto D'Alessandro and Philippe Deloron and Meghna Desai and Graciela Diap and Abdoulaye A. Djimde and Grant Dorsey and Ogobara K. Doumbo and Emmanuelle Espi\'{e} and Jean Francois Etard and Caterina I. Fanello and Jean Fran\c{c}ois Faucher and Babacar Faye and Jennifer A. Flegg and Oumar Gaye and Peter W. Gething and Raquel Gonz\'{a}lez and Francesco Grandesso and Philippe J. Guerin and Jean Paul Guthmann and Sally Hamour and Armedy Ronny Hasugian and Simon I. Hay and Georgina S. Humphreys and Vincent Jullien and Elizabeth Juma and Moses R. Kamya and Corine Karema and Jean R. Kiechel and Peter G. Kremsner and Sanjeev Krishna and Val\'{e}rie Lameyre and Laminou M. Ibrahim and Sue J. Lee and Bertrand Lell and Andreas Martensson and Achille Massougbodji and Herv\'{e} Menan and Didier M\'{e}nard and Clara Men\'{e}ndez and Martin Meremikwu and Clarissa Moreira and Carolyn Nabasumba and Michael Nambozi and Jean Louis Ndiaye and Frederic Nikiema and Christian Nsanzabana and Francine Ntoumi and Bernhards R. Ogutu and Piero Olliaro and Lyda Osorio and Jean Bosco Ou\'{e}draogo and Louis K. Penali and Mbaye Pene and Loretxu Pinoges and Patrice Piola and Ric N. Price and Cally Roper and Philip J. Rosenthal and Claude Emile Rwagacondo and Albert Same-Ekobo and Birgit Schramm and Amadou Seck and Bhawna Sharma and Carol Hopkins Sibley and V\'{e}ronique Sinou and Sodiomon B. Sirima and Jeffery J. Smith and Frank Smithuis and Fabrice A. Som\'{e} and Doudou Sow and Sarah G. Staedke and Kasia Stepniewska and Todd D. Swarthout and Khadime Sylla and Ambrose O. Talisuna and Joel Tarning and Walter R. J. Taylor and Emmanuel A. Temu and Julie I. Thwing and Emiliana Tjitra and Roger C. K. Tine and Halidou Tinto and Michel T. Vaillant and Neena Valecha and Ingrid Van Broek and Nicholas J. White and Adoke Yeka and Issaka Zongo},

doi = {10.1186/s12916-015-0301-z},

issn = {17417015},

year  = {2015},

date = {2015-01-01},

journal = {BMC Medicine},

volume = {13},

issue = {1},

publisher = {BioMed Central Ltd.},

abstract = {Background: Artesunate-amodiaquine (AS-AQ) is one of the most widely used artemisinin-based combination therapies (ACTs) to treat uncomplicated Plasmodium falciparum malaria in Africa. We investigated the impact of different dosing strategies on the efficacy of this combination for the treatment of falciparum malaria. Methods: Individual patient data from AS-AQ clinical trials were pooled using the WorldWide Antimalarial Resistance Network (WWARN) standardised methodology. Risk factors for treatment failure were identified using a Cox regression model with shared frailty across study sites. Results: Forty-three studies representing 9,106 treatments from 1999-2012 were included in the analysis; 4,138 (45.4%) treatments were with a fixed dose combination with an AQ target dose of 30 mg/kg (FDC), 1,293 (14.2%) with a non-fixed dose combination with an AQ target dose of 25 mg/kg (loose NFDC-25), 2,418 (26.6%) with a non-fixed dose combination with an AQ target dose of 30 mg/kg (loose NFDC-30), and the remaining 1,257 (13.8%) with a co-blistered non-fixed dose combination with an AQ target dose of 30 mg/kg (co-blistered NFDC). The median dose of AQ administered was 32.1 mg/kg [IQR: 25.9-38.2], the highest dose being administered to patients treated with co-blistered NFDC (median = 35.3 mg/kg [IQR: 30.6-43.7]) and the lowest to those treated with loose NFDC-25 (median = 25.0 mg/kg [IQR: 22.7-25.0]). Patients treated with FDC received a median dose of 32.4 mg/kg [IQR: 27-39.0]. After adjusting for reinfections, the corrected antimalarial efficacy on day 28 after treatment was similar for co-blistered NFDC (97.9% [95% confidence interval (CI): 97.0-98.8%]) and FDC (98.1% [95% CI: 97.6%-98.5%]; P = 0.799), but significantly lower for the loose NFDC-25 (93.4% [95% CI: 91.9%-94.9%]), and loose NFDC-30 (95.0% [95% CI: 94.1%-95.9%]) (P \< 0.001 for all comparisons). After controlling for age, AQ dose, baseline parasitemia and region; treatment with loose NFDC-25 was associated with a 3.5-fold greater risk of recrudescence by day 28 (adjusted hazard ratio},

keywords = {Amodiaquine, Artesunate, Dosing, Drug Resistance, Efficacy, Malaria, Plasmodium falciparum},

pubstate = {published},

tppubtype = {article}

}